Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy

Jun Wei, Swati Bhattacharyya, Warren G. Tourtellotte, John Varga*

*Corresponding author for this work

Research output: Contribution to journalReview article

116 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) is a complex and incompletely understood disease associated with fibrosis in multiple organs. Recent findings identify transforming growth factor-ß (TGF-ß), Wnt ligands, toll-like receptor-mediated signaling, hypoxia, type I interferon, type 2 immune responses and mechanical stress as extracellular cues that modulate fibroblast function and differentiation, and as potential targets for therapy. Moreover, fibrillin-1 has a major role in storing and regulating the bioavailability of TGF-ß and other cytokines, and fibrillin-1 mutations are implicated in a congenital form of scleroderma called stiff skin syndrome. Fibrosis is due not only to the activation of tissue-resident fibroblasts and their transdifferentiation into myofibroblasts, but also the differentiation of bone marrow-derived fibrocytes, and transition of endothelial and epithelial cells, pericytes and adipocytes into activated mesenchymal cells. These responses are modulated by signaling mediators and microRNAs that amplify or inhibit TGF-ß and Wnt signaling. Gain-of-function and loss-of-function abnormalities of these mediators may account for the characteristic activated phenotype of SSc fibroblasts. The nuclear orphan receptor PPAR-γ plays a particularly important role in limiting the duration and intensity of fibroblast activation and differentiation, and impaired PPAR-γ expression or function in SSc may underlie the uncontrolled progression of fibrosis. Identifying the perturbations in signaling pathways, mediators and differentiation programs that are responsible for SSc tissue damage allows their selective targeting. This in turn opens the door for therapies utilizing novel compounds, or drug repurposing by innovative uses of already-approved drugs. In view of the heterogeneous clinical presentation and unpredictable course of SSc, as well as its complex pathogenesis, only robust clinical trials incorporating the judicious application of biomarkers will be able to clarify the clinical utility of these innovative approaches.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalAutoimmunity Reviews
Volume10
Issue number5
DOIs
StatePublished - Mar 1 2011

Fingerprint

Systemic Scleroderma
Fibrosis
Transforming Growth Factors
Fibroblasts
Peroxisome Proliferator-Activated Receptors
Drug Repositioning
Orphan Nuclear Receptors
Therapeutics
Pericytes
Mechanical Stress
Myofibroblasts
Toll-Like Receptors
MicroRNAs
Adipocytes
Biological Availability
Interferon-gamma
Cues
Endothelial Cells
Biomarkers
Bone Marrow

Keywords

  • Collagen
  • Fibroblast
  • Fibrosis
  • Systemic sclerosis
  • TGF-ß
  • Wnt

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{3f95eda3048848c7b4c0beaa5bb78fbe,
title = "Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy",
abstract = "Systemic sclerosis (SSc) is a complex and incompletely understood disease associated with fibrosis in multiple organs. Recent findings identify transforming growth factor-{\ss} (TGF-{\ss}), Wnt ligands, toll-like receptor-mediated signaling, hypoxia, type I interferon, type 2 immune responses and mechanical stress as extracellular cues that modulate fibroblast function and differentiation, and as potential targets for therapy. Moreover, fibrillin-1 has a major role in storing and regulating the bioavailability of TGF-{\ss} and other cytokines, and fibrillin-1 mutations are implicated in a congenital form of scleroderma called stiff skin syndrome. Fibrosis is due not only to the activation of tissue-resident fibroblasts and their transdifferentiation into myofibroblasts, but also the differentiation of bone marrow-derived fibrocytes, and transition of endothelial and epithelial cells, pericytes and adipocytes into activated mesenchymal cells. These responses are modulated by signaling mediators and microRNAs that amplify or inhibit TGF-{\ss} and Wnt signaling. Gain-of-function and loss-of-function abnormalities of these mediators may account for the characteristic activated phenotype of SSc fibroblasts. The nuclear orphan receptor PPAR-γ plays a particularly important role in limiting the duration and intensity of fibroblast activation and differentiation, and impaired PPAR-γ expression or function in SSc may underlie the uncontrolled progression of fibrosis. Identifying the perturbations in signaling pathways, mediators and differentiation programs that are responsible for SSc tissue damage allows their selective targeting. This in turn opens the door for therapies utilizing novel compounds, or drug repurposing by innovative uses of already-approved drugs. In view of the heterogeneous clinical presentation and unpredictable course of SSc, as well as its complex pathogenesis, only robust clinical trials incorporating the judicious application of biomarkers will be able to clarify the clinical utility of these innovative approaches.",
keywords = "Collagen, Fibroblast, Fibrosis, Systemic sclerosis, TGF-{\ss}, Wnt",
author = "Jun Wei and Swati Bhattacharyya and Tourtellotte, {Warren G.} and John Varga",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.autrev.2010.09.015",
language = "English (US)",
volume = "10",
pages = "267--275",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "5",

}

Fibrosis in systemic sclerosis : Emerging concepts and implications for targeted therapy. / Wei, Jun; Bhattacharyya, Swati; Tourtellotte, Warren G.; Varga, John.

In: Autoimmunity Reviews, Vol. 10, No. 5, 01.03.2011, p. 267-275.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Fibrosis in systemic sclerosis

T2 - Emerging concepts and implications for targeted therapy

AU - Wei, Jun

AU - Bhattacharyya, Swati

AU - Tourtellotte, Warren G.

AU - Varga, John

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Systemic sclerosis (SSc) is a complex and incompletely understood disease associated with fibrosis in multiple organs. Recent findings identify transforming growth factor-ß (TGF-ß), Wnt ligands, toll-like receptor-mediated signaling, hypoxia, type I interferon, type 2 immune responses and mechanical stress as extracellular cues that modulate fibroblast function and differentiation, and as potential targets for therapy. Moreover, fibrillin-1 has a major role in storing and regulating the bioavailability of TGF-ß and other cytokines, and fibrillin-1 mutations are implicated in a congenital form of scleroderma called stiff skin syndrome. Fibrosis is due not only to the activation of tissue-resident fibroblasts and their transdifferentiation into myofibroblasts, but also the differentiation of bone marrow-derived fibrocytes, and transition of endothelial and epithelial cells, pericytes and adipocytes into activated mesenchymal cells. These responses are modulated by signaling mediators and microRNAs that amplify or inhibit TGF-ß and Wnt signaling. Gain-of-function and loss-of-function abnormalities of these mediators may account for the characteristic activated phenotype of SSc fibroblasts. The nuclear orphan receptor PPAR-γ plays a particularly important role in limiting the duration and intensity of fibroblast activation and differentiation, and impaired PPAR-γ expression or function in SSc may underlie the uncontrolled progression of fibrosis. Identifying the perturbations in signaling pathways, mediators and differentiation programs that are responsible for SSc tissue damage allows their selective targeting. This in turn opens the door for therapies utilizing novel compounds, or drug repurposing by innovative uses of already-approved drugs. In view of the heterogeneous clinical presentation and unpredictable course of SSc, as well as its complex pathogenesis, only robust clinical trials incorporating the judicious application of biomarkers will be able to clarify the clinical utility of these innovative approaches.

AB - Systemic sclerosis (SSc) is a complex and incompletely understood disease associated with fibrosis in multiple organs. Recent findings identify transforming growth factor-ß (TGF-ß), Wnt ligands, toll-like receptor-mediated signaling, hypoxia, type I interferon, type 2 immune responses and mechanical stress as extracellular cues that modulate fibroblast function and differentiation, and as potential targets for therapy. Moreover, fibrillin-1 has a major role in storing and regulating the bioavailability of TGF-ß and other cytokines, and fibrillin-1 mutations are implicated in a congenital form of scleroderma called stiff skin syndrome. Fibrosis is due not only to the activation of tissue-resident fibroblasts and their transdifferentiation into myofibroblasts, but also the differentiation of bone marrow-derived fibrocytes, and transition of endothelial and epithelial cells, pericytes and adipocytes into activated mesenchymal cells. These responses are modulated by signaling mediators and microRNAs that amplify or inhibit TGF-ß and Wnt signaling. Gain-of-function and loss-of-function abnormalities of these mediators may account for the characteristic activated phenotype of SSc fibroblasts. The nuclear orphan receptor PPAR-γ plays a particularly important role in limiting the duration and intensity of fibroblast activation and differentiation, and impaired PPAR-γ expression or function in SSc may underlie the uncontrolled progression of fibrosis. Identifying the perturbations in signaling pathways, mediators and differentiation programs that are responsible for SSc tissue damage allows their selective targeting. This in turn opens the door for therapies utilizing novel compounds, or drug repurposing by innovative uses of already-approved drugs. In view of the heterogeneous clinical presentation and unpredictable course of SSc, as well as its complex pathogenesis, only robust clinical trials incorporating the judicious application of biomarkers will be able to clarify the clinical utility of these innovative approaches.

KW - Collagen

KW - Fibroblast

KW - Fibrosis

KW - Systemic sclerosis

KW - TGF-ß

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=79952037889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952037889&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2010.09.015

DO - 10.1016/j.autrev.2010.09.015

M3 - Review article

C2 - 20863909

AN - SCOPUS:79952037889

VL - 10

SP - 267

EP - 275

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 5

ER -